Has Linda Collado, MD received payments from drug or device companies?

Yes. Drug and device makers reported $27,813 in general payments to Linda Collado, MD across 177 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Linda Collado, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Linda Collado, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Linda Collado, MD

Psychiatry · Coral Gables, FLNPI 1588958391

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $17,958 of the $27,813 with a category attached, or 64.6%. E.r. Squibb & Sons, L.L.C. accounts for 85.0% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $25,262, more than ten times the $223 reported in 2019. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,813in general payments, 2019–2025

Across 177 payments — averaging $157.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$24K
AbbVie$749
Alkermes, Inc.$641
Neurocrine Biosciences, Inc.$628
Otsuka America Pharmaceutical, Inc.$473
Teva Pharmaceuticals USA, Inc.$422
plus $1K from 17 others

$78,075in research payments, 2019–2025

Across 22 payments — averaging $3548.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$65K
Amgen$13K

What the payments were for

Consulting fees$17,95865%
Speaking & faculty fees$2,76910%
Travel & lodging$1,8917%
Food & beverage$5,19419%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	35	$23,649
AbbVie	39	$749
Alkermes, Inc.	11	$641
Neurocrine Biosciences, Inc.	8	$628
Otsuka America Pharmaceutical, Inc.	23	$473
Teva Pharmaceuticals USA, Inc.	17	$422
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$203
Johnson & Johnson	10	$196
Lundbeck LLC	7	$165
Luye Pharma (USA) Ltd.	2	$136
Boehringer Ingelheim	1	$118
Indivior Inc.	5	$108
Sunovion Pharmaceuticals Inc.	3	$54
Axsome Therapeutics, Inc.	2	$54
Vanda Pharmaceuticals Inc.	1	$36
TMS Neurohealth Centers Inc.	1	$29
Ironshore Pharmaceuticals Inc.	2	$28
Idorsia Pharmaceuticals US Inc	1	$25
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$23
Collegium Pharmaceutical, Inc.	1	$22
Noven Therapeutics, LLC	1	$22
Corium, LLC	1	$18
Takeda Pharmaceuticals U.S.A., Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,813 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida →

Medicare billing

Part B allowed, 2024

$193,332

Medicare patients

Services billed

901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Duloxetine Hcl	12	$342
Mirtazapine	13	$156

Paid to pharmacies, not to this prescriber.

Other psychiatry in Coral Gables

Ilan MelnickCoral Gables$2.8M
Moraima TrujilloCoral Gables$121K
Andrew CutlerLakewood Ranch$5.7M
Richard JacksonBoca Raton$3.6M
Todd BroderSt Augustine$1.6M
Heather LuingSaint Augustine$1.5M
Todd GatesWest Melbourne$1.2M
Lawrence ReccoppaGainesville$968K
Thomas ValenteLeesburg$967K
Michelle ScargleClearwater$926K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →